The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/II study of the investigational aurora A kinase (AAK) inhibitor MLN8237 (alisertib) in patients (pts) with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), breast cancer (BrC), head/neck cancer (H&N), and gastroesophageal (GE) adenocarcinoma: Preliminary phase II results.
Peter Lee
No relevant relationships to disclose
Ricardo H. Alvarez
No relevant relationships to disclose
Bohuslav Melichar
No relevant relationships to disclose
Petr Zatloukal
No relevant relationships to disclose
Antoine Adenis
Consultant or Advisory Role - Novartis; Sanofi
Honoraria - Amgen; Bayer; Pfizer; Sanofi
Research Funding - Novartis
Jaafar Bennouna
No relevant relationships to disclose
Claudia Schusterbauer
Employment or Leadership Position - Millennium
Bin Zhang
Employment or Leadership Position - Millennium
Ely Benaim
Employment or Leadership Position - Millennium
Stock Ownership - Millennium
Peter J. Rosen
Research Funding - Millennium